Skip to main content

Table 3 Baseline characteristics in the propensity score-matched paliperidone ER, risperidone and pooled placebo groups

From: Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis

 

Paliperidone ER

6-12 mg/day

n = 179

Risperidone

2-4 mg/day

n = 113

Risperidone

4-6 mg/day

n = 129

Pooled Placebo

n = 217

Age, years, mean (SD)

37.4 (11.3)

37.8 (10.6)

37.1 (10.1)

37.4 (10.4)

Female, n (%)

45 (25.1)

31 (27.4)

32 (24.8)

41 (18.9)

Race, n (%)

    

   Caucasian

136 (76.0)

83 (73.5)

99 (76.7)

138 (63.6)

   Other

43 (24.0)

30 (26.5)

30 (23.3)

79 (36.4)

BMI, mean (SD), kg/m2

25.2 (4.7)

25.5 (3.3)

25.5 (3.4)

25.1 (4.2)

PANSS total score, mean (SD)

94.3 (11.9)

94.4 (15.2)

96.2 (16.6)

93.4 (12.2)

CGI-S score, mean (SD)

4.8 (0.7)

4.8 (0.6)

4.8 (0.7)

4.7 (0.8)

  1. BMI = body mass index; PANSS = Positive and Negative Syndrome Scale; CGI-S = Clinical Global Impressions—Severity.
  2. All the p values are >0.05 for the group comparisons. p values are from ANOVA models with factor treatment for continuous variables and chi-square test for categorical variables.